← All trials
NCT07068516
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 20, 2025
- Primary completion
- Jun 30, 2027
- Completion date
- Jun 30, 2030
- First posted
- Jul 16, 2025
- Last posted
- Jul 16, 2025
- Enrollment
- 470
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- University of Electronic Science and Technology of ChinaCollaborator
- Chinese Academy of Medical SciencesSponsor investigator
- Dalian Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.